List of Figures

Figure 1: Epidemiology and Market Methodology
Figure 2: Symptoms of Obesity in Adults
Figure 3: Symptoms of Obesity in Children and Adolescents
Figure 4: Symptoms of Morbid Obesity
Figure 5: Risk Factors of Obesity
Figure 6: Causes of Obesity
Figure 7: Neural Pathways and Systems Controlling Ingestive Behavior and Energy Balance
Figure 8: Role of lipotoxicity and inflammation on obesity
Figure 9: Role of inflammation and immune dysfunction in obesity
Figure 10: Medical Complications of Obesity
Figure 11: Clinical care pathway for overweight and obese adults
Figure 12: Total Prevalent Cases of Obesity in Adults in the 7MM (2019–2032)
Figure 13: Total Prevalent Cases of Obesity in Children in the 7MM (2019–2032)
Figure 14: Total Prevalent Cases of Obesity in Adults in the United States, in Millions(2019–2032)
Figure 15: Total Prevalent Cases of Obesity in Children in the United States, in Millions(2019–2032)
Figure 16: Total Obesity patients seeking help in adults in the United States (2019–2032)
Figure 17: Total Obesity patients seeking help in children in the United States (2019–2032)
Figure 18: Total Treated Cases of Obesity in Adults the United States (2019–2032)
Figure 19: Total Treated Cases of Obesity in Children in the United States (2019–2032)
Figure 20: Total Prevalent Cases of Obesity in Adults in EU-5 (2019–2032)
Figure 21: Total Prevalent Cases of Obesity in Children in EU-5 (2019–2032)
Figure 22: Total Obesity patients seeking help in Adults in EU-5 (2019–2032)
Figure 23: Total Obesity patients seeking help in Children in EU-5 (2019–2032)
Figure 24: Total Treated Cases of Obesity in Adults in EU5 (2019–2032)
Figure 25: Total Treated Cases of Obesity in Children in EU5 (2019–2032)
Figure 26: Total Prevalent Cases of Obesity in Adults Japan (2019–2032)
Figure 27: Total Prevalent Cases of Obesity in Children Japan (2019–2032)
Figure 28: Total Obesity patients seeking help in Adults in Japan (2019–2032)
Figure 29: Total Children Obesity patients seeking help in Adults in Japan (2019–2032)
Figure 30: Total Treated Cases of Obesity in Adults Japan (2019–2032)
Figure 31: Total Treated Cases of Obesity in Children in Japan (2019–2032)
Figure 32: Percentage of Patients Losing ?5% and ?10% of Body Weight From Randomization After 1-year Treatment*
Figure 33: Mean Change in Risk Factors From Randomization Following 1-year Treatment* Population as a Whole
Figure 34: Percentage of Patients Losing ? 5% and ? 10% of Body Weight From Randomization After 2-year Treatment*
Figure 35: Mean Change From Baseline Body Weight (Kg) Over Time*
Figure 36: Mean Change in Risk Factors From Randomization Following 4-year Treatment*
Figure 37: Incidence Rate of Diabetes at Year 4 by OGTT Status at Baseline*
Figure 38: Percentages of Patients With ?5% and ?10% Decrease in Body Mass Index and Body Weight After 1-year Treatment* (Protocol NM16189)
Figure 39: Weight Loss at Year 1 in Study 1 and 2
Figure 40: Change in Weight in 56-week Trials With Contrave (ITT/LOCF*)
Figure 41: Change in Markers Of Cardiovascular and Metabolic Parameters From Baseline in 56-week Trials With Contrave 32 mg/360 mg (COR-I and COR-BMOD)*
Figure 42: Changes in Cardiometabolic Parameters and Waist Circumference in Patients With Type 2 Diabetes Mellitus in a 56-week Trial With Contrave 32 mg/360 mg (COR-Diabetes)
Figure 43: Changes in Weight at Week 56 for Studies 1, 2, and 3
Figure 44: Changes in Weight at Week 56 and Week 160 for study 1 (Subset of Patients With Abnormal Blood Glucose at Randomization)
Figure 45: Mean Changes in Anthropometry and Cardiometabolic Parameters in Study 1 (Patient Without Diabetes)
Figure 46: Mean Changes in Anthropometry and Cardiometabolic Parameters in Study 2 (Patient With Diabetes Mellitus)
Figure 47: The Time Course of Change in BMI SDS With Saxenda and Placebo From Baseline Through Week 56
Figure 48: Changes in Weight and BMI at Week 56 for Study 4 (Pediatric Patients Ages 12 to Less Than 18)
Figure 49: Mean Changes in Anthropometry and Cardiometabolic Parameters in Study 4 (Pediatric Patients Ages 12 to Less Than 18)
Figure 50: Body Weight (kg) – Proportion of Patients Achieving at least 10% Weight Loss From Baseline at 1-year in Study 1 and Study 2
Figure 51: Body Weight (kg) – Proportion of Patients Achieving at least 10% Weight Loss From Baseline at 1 year in Study 1 and Study 2
Figure 52: Mean Percentage Change in Body Weight From Baseline by Visit (Study 1 [n=9] and
Figure 53: Daily Hunger Scores – Change from Baseline at 1-year in Subjects Aged ?12 Years in Study 1 and Study 2 With Available Hunger Data
Figure 54: Market Size of Obesity in the 7MM, USD Million (2019–2032)
Figure 55: 7MM Market Size of Obesity by Therapies in USD Million (2019–2032)
Figure 56: Market Size of Obesity in the United States, USD Million (2019–2032)
Figure 57: Market Size of Obesity by Therapies in the United States, in USD Million (2019–2032)
Figure 58: Market Size of Obesity in EU-5, USD Million (2019–2032)
Figure 59: Market Size of Obesity by Therapies in EU-5, in USD Million (2019–2032)
Figure 60: Market Size of Obesity in Japan, USD Million (2019–2032)
Figure 61: Market Size of Obesity by Therapies, in Japan in USD Million (2019–2032)
Figure 62: Market Drivers
Figure 63: Market Barriers
Figure 64: Unmet Needs

List of Tables

Table 1: Key Events
Table 2: Classification of Overweight and Obesity, and Associated Disease Risk
Table 3: Diagnostic Criteria for Metabolic Syndrome*
Table 4: Diagnostic and Medical management of Obesity
Table 5: Total Prevalent Cases of Obesity in the 7MM, in Millions (2019–2032)
Table 6: Total Prevalent Cases of Obesity in the United States, in Millions (2019–2032)
Table 7: Total Obesity patients seeking help in the United States, in Millions (2019–2032)
Table 8: Total Treated cases of Obesity in the United States, in Thousands(2019–2032)
Table 9: Total Prevalent Cases of Obesity in EU-5, in Millions (2019–2032)
Table 10: Total Obesity patients seeking help in EU5, in Millions (2019–2032)
Table 11: Total Treated cases of obesity in EU5, in Thousands (2019–2032)
Table 12: Total Diagnosed Prevalent Cases of Obesity in Japan, in Millions (2019–2032)
Table 13: Total Obesity patients seeking help in Japan, in Thousands(2019–2032)
Table 14: Total Treated cases of Obesity in Japan, in Thousands (2019–2032)
Table 15: Key competitors: Marketed drugs
Table 16: Xenical (orlistat), Clinical Trial Description, 2022
Table 17: Qsymia (phentermine-topiramate), Clinical Trial Description, 2022
Table 18: Contrave (naltrexone-bupropion), Clinical Trial Description, 2022
Table 19: Saxenda (liraglutide), Clinical Trial Description, 2022
Table 20: Wegovy (Simaglutide), Clinical Trial Description, 2022
Table 21: Imcivree (setmelanotide)/ RM-493, Clinical Trial Description, 2022
Table 22: Key Emerging Therapies
Table 23: Other Notable Emerging Therapies
Table 24: Semaglutide Oral, Clinical Trial Description, 2022
Table 25: Tirzepatide, Clinical Trial Description, 2022
Table 26: Cotadutide, Clinical Trial Description, 2022
Table 27: BI 456906, Clinical Trial Description, 2022
Table 28: RZL-012, Clinical Trial Description, 2022
Table 29: NNC0174-0833, Clinical Trial Description, 2022
Table 30: Pemvidutide, Clinical Trial Description, 2022
Table 31: Tesomet, Clinical Trial Description, 2022
Table 32: Xla1, Clinical Trial Description, 2022
Table 33: IBI362, Clinical Trial Description, 2022
Table 34: HSG4112, Clinical Trial Description, 2022
Table 35: S-237648, Clinical Trial Description, 2022
Table 36: ARD-101, Clinical Trial Description, 2022
Table 37: LY 3437943, Clinical Trial Description, 2022
Table 38: Leucine/sildenafil, Clinical Trial Description, 2022
Table 39: MBL949, Clinical Trial Description, 2022
Table 40: TG103, Clinical Trial Description, 2022
Table 41: SHR20004, Clinical Trial Description, 2022
Table 42: CT-868, Clinical Trial Description, 2022
Table 43: PF-06882961, Clinical Trial Description, 2022
Table 44: NNC0165-1875, Clinical Trial Description, 2021
Table 45: XW003, Clinical Trial Description, 2022
Table 46: LY3502970, Clinical Trial Description, 2022
Table 47: EMP16-01, Clinical Trial Description, 2022
Table 48: NNC-0480-0389 , Clinical Trial Description, 2022
Table 49: NNC0247 0829, Clinical Trial Description, 2022
Table 50: 7MM Market Size of Obesity in the 7MM in USD Million (2019–2032)
Table 51: 7MM Market Size of Obesity by Therapies in USD Million (2019–2032)
Table 52: Market Size of Obesity in the United States, in USD Million (2019–2032)
Table 53: Market Size of Obesity by Therapies in the United States, in USD Million (2019–2032)
Table 54: Market Size of Obesity in EU-5, in USD Million (2019–2032)
Table 55: Market Size of Obesity by Therapies in EU-5, in USD Million (2019–2032)
Table 56: Market Size of Obesity in Japan, in USD Million (2019–2032)
Table 57: Market Size of Obesity by Therapies in Japan, in USD Million (2019–2032)